Why the study?
Does a novel mass spectrometry immunoassay reveal lower levels of bioactive BNP 1-32 compared to standard immunoreactive BNP assays in patients with heart failure?
Population
12 patients with heart failure
Comparison
Quantitative mass spectrometry immunoassay to… vs Biosite assay for immunoreactive BNP
Design
Other
Authors
Loading...
Standard BNP assays may overestimate bioactive levels in HF; hypothesis-generating for natriuretic resistance mechanisms and assay validation.
Does a novel mass spectrometry immunoassay reveal lower levels of bioactive BNP 1-32 compared to standard immunoreactive BNP assays in patients with heart failure?
Standard BNP assays significantly overestimate the levels of bioactive BNP 1-32 in heart failure patients, which may explain the lack of natriuretic response despite high measured BNP levels.
Niederkofler et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: